Humana

Trimming a winner is harder than buying one. Here's how to separate thesis decay, valuation stretch, and position-size risk — and act on the right one.

Restructuring charges are supposed to be non-recurring. When they recur year after year, they stop being noise and start telling you something important about the business.

Two ratios, one stock, opposite stories. A practical framework for choosing between P/E and EV/EBITDA — and knowing when each one is quietly misleading you.

SEC rules force companies to name customers above 10% of revenue. Here's how to use that disclosure to size cyclical and single-point-of-failure risk in your holdings.

A practical guide to reading an insurer's combined ratio — when the underwriting business actually makes money, and when the profits are really coming from float.

A reverse DCF flips valuation on its head: instead of guessing growth, you solve for the rate baked into today's price — then ask if it's even plausible.